Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

ions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at www.provenge.com or call 1-877-336-3736.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in men in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 240,890 new cases and approximately 33,720 men expected to die from the disease in 2011.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is t
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 New interactive ... innovative thought leaders of the medical device industry ... conference and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These ... industry professionals practical presentations and implementable solutions on ...
(Date:5/17/2013)... Miami, FL (PRWEB) May 17, 2013 Men’s ... at La-roche Posay ) and has been known ... itself. Although some men may be far from puberty, other ... be clogging pores, causing breakouts, and threatening skin with unsightly ... with advice from Men’s Health on how to ...
(Date:5/17/2013)... Darrington, WA (PRWEB) May 17, 2013 Tooth ... 5th graders showing active signs of the disease. The World ... children and nearly 100% of adults have cavities. What are ... Research is showing a strong connection between the oral ... why is this disease so rampant, yet it is also ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... , STOCKHOLM, ... European Investment Fund (EIF) has entered into a,co-investment agreement ... Karolinska Development and used to invest in the company,s,portfolio ... to invest 26.7 M Euros in the co-investment fund. ...
... Most people would like to be able to charge ... not too often. A recent discovery made by UC ... that could do just this. In recent ... Bandaru, a professor in the UCSD Department of Mechanical ...
... , BETHESDA, Md., Nov. 19 ... for diabetes therapy, and a provider of technical and regulatory ... today it closed the previously reported $6.3 million registered direct ... stock and warrants to purchase up to 1,104,348 additional shares ...
Cached Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Nanotube defects equal better energy and storage systems 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3
(Date:5/18/2013)... 2013) The AGA Research Foundation is honored to ... Award in Digestive Cancer, which will support Andrew D. ... the University of Pennsylvania, Philadelphia, as he furthers his ... regeneration and cancer progression. , "The AGA Research Foundation ... two distinguished clinicians and AGA Legacy Society members," said ...
(Date:5/18/2013)... 2013) Research presented today at Digestive Disease Week ... findings about the impact of coffee on autoimmune disease ... coffee consumption recently has been associated with reduced risk ... few more cups of java each month also correlate ... Researchers at the Mayo Clinic, Rochester, MN, linked coffee ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) Research presented ... for managing digestive health through diet and lifestyle. ... often plagued by reduced muscle strength, fatigue and ... even when patients are in remission. A randomized, ... time that vitamin D supplementation corresponded to significant ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3
... A groundbreaking study lead by Chapman University professor Brennan ... will be published in the May 5th edition ... reproductive biology. It is the first such study ... the USA, the postponement of childbearing is reflective of ...
... The American Academy of OtolaryngologyHead and Neck Surgery (AAO-HNS) ... physicians. Clinical indicators for otolaryngology serve as a checklist ... clinical departments. The Clinical Indicators are created by the ... define a basis of medical necessity for a range ...
... LSU,s Mark Batzer, along with research associate Jerilyn Walker and ... orangutans are host to ancient jumping genes called Alu, which ... done in collaboration with the Zoological Society of San Diego ... featured in the new open access journal Mobile DNA ...
Cached Biology News:New study published on fertility awareness among American university students 2LSU research finds orangutans host ancient jumping genes 2
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human CXCL14/BRAK Affinity Purified Polyclonal Ab...
Biology Products: